Evotec SE Adjusts 2025 Revenue Guidance Amid Strategic Repositioning

Evotec AG ( (EVO) ) just unveiled an update.

On July 21, 2025, Evotec SE announced an adjustment to its revenue guidance for the fiscal year 2025, reducing the expected range to €760–800 million from the previous €840–880 million. Despite this, the company confirmed its profit guidance, with R&D expenditures and adjusted EBITDA expectations remaining unchanged. The revision is attributed to a change in revenue mix and significant cost savings, with technology licensing expected to play a more substantial role in the company’s strategic repositioning. The company is taking steps to address challenges in its Shared R&D base business, which continues to face a difficult market environment.

The most recent analyst rating on (EVO) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.

Spark’s Take on EVO Stock

According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.

The overall stock score of 49 reflects significant financial challenges, particularly regarding profitability and cash flow. While technical indicators suggest some stability, valuation concerns due to negative earnings and lack of dividends weigh heavily. The positive aspects from the earnings call, such as strong segment growth and strategic progress, offer some optimism but are overshadowed by broader financial issues.

To see Spark’s full report on EVO stock, click here.

More about Evotec AG

Evotec SE is a biotechnology company based in Hamburg, Germany, primarily engaged in drug discovery and development solutions. The company focuses on technology licensing and shared R&D services, aiming to transform its business towards sustainable profitable growth.

Average Trading Volume: 129,075

Technical Sentiment Signal: Sell

Current Market Cap: $1.54B

Learn more about EVO stock on TipRanks’ Stock Analysis page.